Tumor Microenvironment & Lymph Node Simulator (2D Stochastic Dynamic Engine)
60 FPS Real-time
Synthetic Neoepitopes
34
mRNA-4157 concatemer capacity (Max 34 clonal neoepitopes)
HLA-A*02 Affinity (IC50)
18 nM
MHC-I peptide binding strength (<50nM = strong binder)
Tumor Mutational Burden
16.4 mut/Mb
Clonal somatic SNV density driving native immunogenicity
PD-L1 Expression Baseline
48%
Tumor cell surface PD-L1 density triggering T-cell exhaustion
Dynamic Kaplan-Meier Survival Modeling (KEYNOTE-942 Benchmark)
Stage III/IV Resected
Survival Probability vs. Follow-up Months
mRNA-4157 + Pembro (Simulated)
Pembrolizumab Alone
Standard Resection / Placebo
Hazard Ratio (HR)
0.56
95% CI (0.31 - 0.94) vs. Monotherapy
3-Year RFS Rate
74.8%
+19.2% absolute gain vs. Pembro
Distant Met Reduction
65.0%
HR 0.35 (95% CI 0.17 - 0.72)
CD8+ Cytotoxic T-Lymphocyte #14
Active / Cytolytic
TCR Specificity: NeoEpitope #07 (BRAF-V600E)
Perforin/Granzyme Reservoir: 92%
PD-1 Receptor State: mAb Blocked (No Anergy)
Clonal Division Index: 4th Generation
Biomolecular Mechanism of Action:
Individualized mRNA-4157 encodes a synthetic single mRNA sequence containing up to 34 patient-specific neoantigens identified via whole-exome sequencing (WES). Dendritic cells translate the mRNA, cleave peptides via the proteasome, and cross-present neoepitopes on MHC Class I molecules. Concurrently, pembrolizumab binds the PD-1 receptor on CD8+ T-cells, sterically hindering PD-L1 engagement by residual melanoma micro-colonies and preventing tumor-mediated adaptive immune resistance.
KEYNOTE-942 / mRNA-4157-P201 Trial Corroboration
In the landmark Phase 2b trial, personalized mRNA-4157 combined with pembrolizumab demonstrated a 44% reduction in risk of recurrence or death (HR=0.56, p=0.053) and a 65% reduction in distant metastasis (HR=0.35) at 3 years compared to pembrolizumab monotherapy in resected Stage III/IV melanoma.